The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia

Blood

Volumn 97, Issue 11, 2001, Pages 3370-3379

  Patte, Catherine ^{a,b,c,d,e,f,g,h,i}   Auperin, Anne ^{a,b,c,d,e,f,g,h,i}   Michon, Jean ^{a,b,c,d,e,f,g,h,i}   Behrendt, Henk ^{a,b,c,d,e,f,g,h,i}   Leverger, Guy ^{a,b,c,d,e,f,g,h,i}   Frappaz, Didier ^{a,b,c,d,e,f,g,h,i}   Lutz, Patrick ^{a,b,c,d,e,f,g,h,i}   Coze, Carole ^{a,b,c,d,e,f,g,h,i}   Perel, Yves ^{a,b,c,d,e,f,g,h,i}   Raphaël, Marline ^{a,b,c,d,e,f,g,h,i}   Terrier Lacombe, Marie Josée ^{a,b,c,d,e,f,g,h,i}  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e CENTRE LÉON BÉRARD   (France)

^f Institut de Puériculture   (France)

^g TIMONE HOSPITAL   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; L3 LEUKEMIA; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035383776     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3370     Document Type: Article

References (39)

1. Patte C, Philip T, Rodary C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol. 1986;4:1219-1226.
2. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991;9: 123-132.
3. Philip T, Hartmann O, Biron P, et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol. 1988;6:1118-1124.
4. Vassal G, Leverger G, Schaison G, Castaigne S. [Acute lymphoblastic leukemia in Burkitt cells: clinical, therapeutic and prognostic aspects.] Nouv Rev Fr Hematol. 1986;28:141-146.
5. Patte C. B-acute lymphoblastic leukemia: the European experience. Int J Pediatr Hematol Oncol. 1998;5:81-88.
6. Patte C, Leverger G, Perel Y, et al. Updated results of the LMB86 protocol of the French Society of Pediatric Oncology (SFOP) for B-cell non Hodgkin's lymphoma with CNS involvement and B ALL [abstract]. Med Pediatr Oncol. 1990;18: 397.
7. Gentet JC, Patte C, Quintana E, et al. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol. 1990;8:661-665.
8. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332-329.
9. Philip T, Pinkerton R, Biron P, et al. Effective multiagent chemotherapy in children with advanced B-cell lymphoma: who remains the high risk patient? Br J Haematol. 1987;65:159-164.
10. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas [letter] [published erratum appears in Lancet. 1988;1(8581): 372]. Lancet. 1988;1:292-293.
11. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
12. Rubino C, Laplanche A, Patte C, Michon J. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma [see comments]. J Natl Cancer Inst. 1998;90:750-755.
13. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis. 1978;31:557-560.
15. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
16. Jenkin RD, Anderson JR, Chilcote RR, et al. The treatment of localized non-Hodgkin's lymphoma in children: a report from the Children's Cancer Study Group. J Clin Oncol. 1984;2:88-97.
17. Meadows AT, Sposto R, Jenkin RD, et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989;7:92-99.
18. Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer. 1980;45:630-637.
19. Patte C, Rodary C, Sarrazin D, et al. [Results of treatment of 178 pediatric non Hodgkin's malignant lymphomas between 1973 and 1978 (author's transl)]. Arch Fr Pediatr. 1981;38:321-327.
20. Patte C, Lemerie J. Malignant B-cell lymphoma. In Barnett MJ, Bloom HJG, Lemerie J, eds. Cancer in Children, Clinical Management. (UICC Handbook). Berlin, Germany: Springer; 1992: 128-140.
21. Link MP, Donaldson SS, Berard CW, et al. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med. 1990;322:1169-1174.
22. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294-3306.
23. Link MP, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with earlystage non-Hodgkin's lymphoma [see comments]. N Engl J Med. 1997;337:1259-1266.
24. Bergeron C, Patte C, Caillaud JM, et al. [Clinical, anatomo-pathologic aspects and therapeutic results in 63 malignant ORL non-Hodgkin's lymphomas in children.] Arch Fr Pediatr. 1989;46:583-587.
25. Pinkerton CR, Hann I, Eden OB, et al. Outcome in stage III non-Hodgkin's lymphoma in children (UKCCSG study NHL86)-how much treatment is needed? United Kingdom Children's Cancer Study Group. Br J Cancer. 1991;64:583-587.
26. Brecher ML, Schwenn MR, Coppes MJ, et al. Fractionated cylophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (SNCCL): a randomized trial of the Pediatric Oncology Group. Med Pediatr Oncol. 1997;29:526-533.
27. Adde M, Shad A, Venzon D, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol. 1998;25:33-39.
28. Mann G, Yakisan E, Schrappe M, et al. Diffuse large B-cell lymphomas in childhood and adolescence: favorable outcome with a Burkitt's lymphoma directed therapy in trial NHL-BFM 90. A report of the BFM group [abstract]. Med Pediatr Oncol. 1997;29:358.
29. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14:925-934.
30. Hutchison RE, Berard CW, Shuster JJ, et al. B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1995;13:2023-2032.
31. Atra A, Imeson JD, Hobson R, et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer. 2000;82: 1396-1402.
32. Todeschini G, Tecchio C, Degani D, et al. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol. 1997;8(suppl 1):77-81.
33. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14:1252-1261.
34. Haddy TB, Adde MA, Magrath IT. CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? J Clin Oncol. 1991;9:1973-1982.
35. Sakiroglu C, Patte C, Michon J, et al. Use of Uricozyme and occurence of metabolic problems during initial phase of the LMB 89 protocol [abstract]. Med Pediatr Oncol. 1997;29:331.
36. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813-1816.
37. Mahmoud HH, Leverger G, Patte C, et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer. 1998;77(suppl 4):18-20.
38. Atra A, Gerrard M, Hobson R, et al. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)-results of the UKCCSG 9003 protocol. Br J Cancer. 1998;77: 2281-2285.
39. Cairo MS, Gerrard M, Patte C, on behalf of the FAB LMB96 International Cooperative Study Group. A new protocol for treatment of mature B-cell lymphoma/leukemia: FAB LMB 96, a SFOP LMB 96/CCG-5961/UKCCSG NHL 9600 international cooperative study [abstract]. Med Pediatr Oncol. 1997;29:357.